New Breakthrough in Liver Cancer Treatment Using Stem Cells

Strategic Insights -

Current study results on liver cancer have shown promising prospects for innovative treatment approaches. A research study published in Frontiers in Cell and Developmental Biology demonstrated the effectiveness of utilizing bone marrow-derived mesenchymal stem cells (BM-MSCs) in conjunction with existing medications, such as cisplatin, to reduce the number of malignant tumor cells in liver cancer patients. The study, conducted by researchers from King Abdulaziz University in Saudi Arabia, aimed to identify more efficient therapeutic approaches while minimizing adverse effects.

Key Takeaways:

  • The study found that BM-MSCs can effectively reduce the number of malignant tumor cells through the induction of an epigenetic impact, with a synergetic effect leading to 74% cell death in vitro.
  • In vivo studies showed a decrease in tumor size and number following treatment with cisplatin and BM-MSCs, with the body weight of mice improving across all treatment groups.
  • The study concluded that both in vitro and in vivo studies showed the synergetic effect of cisplatin and isolated conditioned medium, indicating a potential new treatment approach for liver cancer.
  • The combination treatment of BM-MSCs and cisplatin resulted in a significant improvement in body weight and liver function, with the treatment lasting 18 weeks.
  • The research highlighted the potential of stem cells and existing medications to minimize adverse effects and improve treatment efficacy in liver cancer patients.
  • The study emphasized the need for further research to explore the therapeutic potential of BM-MSCs in liver cancer treatment.

Statistics:

  • 866,000 people were diagnosed with hepatocellular carcinoma (HCC) in 2022 globally.
  • Nearly 42,240 new cases of HCC will be identified in 2025 in the United States.
  • The study found a significant decrease in tumor size and number following treatment with cisplatin and BM-MSCs, with the body weight of mice improving across all treatment groups.
  • The combination treatment resulted in a synergetic effect, leading to 74% cell death in vitro.

Sources:

  • In vivo and in vitro therapeutic evaluation of bone marrow-derived mesenchymal stem cells in liver cancer treatment. Frontiers in Cell and Developmental Biology, 2025,13.
  • King Abdulaziz University Researchers Have Published New Data on Liver Cancer (In vivo and in vitro therapeutic evaluation of bone marrow-derived mesenchymal stem cells in liver cancer treatment). Hematology Week. May 26, 2025; p 2326.